The role of post-remission chemotherapy for older patients with acute myelogenous leukemia
暂无分享,去创建一个
A. Advani | L. Rybicki | M. Sekeres | M. Kalaycio | B. Pohlman | R. Sobecks | R. Abou-Jawde | R. Abou-jawde
[1] S. Fröhling,et al. CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] D. Neuberg,et al. A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group. , 2004, Blood.
[3] D. Linch,et al. Prognostic Implications of the Presence of FLT3 Mutations in Patients with Acute Myeloid Leukemia , 2003, Leukemia & lymphoma.
[4] R. Stone,et al. The Difficult Problem of Acute Myeloid Leukemia in the Older Adult , 2002, CA: a cancer journal for clinicians.
[5] R. Stone,et al. Older adults with acute myeloid leukemia , 2002, Current oncology reports.
[6] Y. Kanda,et al. Prognostic Factors in Elderly Patients with Acute Myelogenous Leukemia: A Single Center Study in Japan , 2002, Leukemia & lymphoma.
[7] H. Kantarjian,et al. Acute myeloid leukemia , 2018, Methods in Molecular Biology.
[8] J. Doroshow,et al. Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study. , 2001, Blood.
[9] F. Ferrara,et al. Acute myeloid leukemia in the elderly: biology and therapeutic strategies. , 2001, Critical reviews in oncology/hematology.
[10] D. Grimwade,et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. , 2001, Blood.
[11] Edward J. Lee,et al. Postremission therapy in older patients with de novo acute myeloid leukemia: a randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine. , 2001, Blood.
[12] Barbara Tripp,et al. Chemotherapy for Acute Myelogenous Leukemia in the Elderly With Cytarabine, Mitoxantrone, and Granulocyte-Macrophage Colony-Stimulating Factor , 2001, American Journal of Clinical Oncology.
[13] E. Estey. How I treat older patients with AML. , 2000, Blood.
[14] C. Willman,et al. Acute myelogenous leukemia and aging. Clinical interactions. , 2000, Hematology/oncology clinics of North America.
[15] W. Hiddemann,et al. Management of acute myeloid leukemia in elderly patients. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] F. Ferrara,et al. Acute myeloid leukemia in the elderly: a critical review of therapeutic approaches and appraisal of results of therapy. , 1998, Leukemia & lymphoma.
[17] P. Sonneveld,et al. Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy--the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] F. Appelbaum,et al. A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: a Southwest oncology group study (9031). , 1998, Blood.
[19] M. Kalaycio. Inpatient management of acute leukemia. , 1997, Cleveland Clinic journal of medicine.
[20] M. Slovak,et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. , 1997, Blood.
[21] H. Rugo,et al. A randomized trial of high- vs standard-dose mitoxantrone with cytarabine in elderly patients with acute myeloid leukemia , 1997, Leukemia.
[22] M. Slovak,et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. , 1997, Blood.
[23] F. Ferrara,et al. Serum LDH value as a predictor of clinical outcome in acute myelogenous leukaemia of the elderly , 1996, British journal of haematology.
[24] J. Bennett,et al. A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (> 55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490). , 1995, Blood.
[25] Stephen L. George,et al. Granulocyte–Macrophage Colony-Stimulating Factor after Initial Chemotherapy for Elderly Patients with Primary Acute Myelogenous Leukemia , 1995 .
[26] T. Hamblin. Disappointments in treating acute leukemia in the elderly. , 1995, The New England journal of medicine.
[27] E. Feldman. Acute myelogenous leukemia in the older patient. , 1995, Seminars in oncology.
[28] R. Mayer,et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. , 1994, The New England journal of medicine.
[29] R. Mayer,et al. The approach to the elderly patient with acute myeloid leukemia. , 1993, Hematology/oncology clinics of North America.
[30] M. Lewis,et al. Mitozantrone and cytosine arabinoside as first‐line therapy in elderly patients with acute myeloid leukaemia , 1991, British journal of haematology.
[31] C. Bloomfield,et al. Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] S. Nimer,et al. Efficacy of intensive chemotherapy for acute myelogenous leukemia associated with a preleukemic syndrome. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] B. Löwenberg,et al. On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] E. Estey,et al. Intensive treatment of acute leukemia in adults 70 years of age and older , 1987, Cancer.
[35] R. Gray,et al. PRINCIPAL RESULTS OF THE MEDICAL RESEARCH COUNCIL'S 8th ACUTE MYELOID LEUKAEMIA TRIAL , 1986, The Lancet.
[36] G Flandrin,et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. , 1985, Annals of internal medicine.
[37] K. Rai,et al. Acute Granulocytic Leukemia in the Elderly , 1976 .
[38] F. Rosner,et al. Letter: Acute granulocytic leukemia in the elderly. , 1976, Archives of internal medicine.
[39] W. Dameshek. Treatment of AGL. , 1969, Archives of internal medicine.
[40] G. Cartwright,et al. To treat or not to treat acute granulocytic leukemia. II. , 1969, Archives of internal medicine.
[41] W. Crosby. To treat or not to treat acute granulocytic leukemia. , 1968, Archives of internal medicine.